Improving outcomes of first-episode psychosis: an overview

被引:204
作者
Fusar-Poli, Paolo [1 ,2 ]
McGorry, Patrick D. [3 ,4 ]
Kane, John M. [5 ,6 ,7 ]
机构
[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, Early Psychosis Intervent & Clin Detect Lab, London, England
[2] South London & Maudsley NHS Fdn Trust, OASIS Serv, London, England
[3] Orygen, Parkville, Vic, Australia
[4] Univ Melbourne, Ctr Youth Mental Hlth, Melbourne, Vic, Australia
[5] Zucker Hillside Hosp, Glen Oaks, NY USA
[6] Hofstra Northwell Sch Med, Dept Psychiat, Hempstead, NY USA
[7] Hofstra Northwell Sch Med, Dept Mol Med, Hempstead, NY USA
关键词
Psychosis; schizophrenia; psychosis risk; clinical high risk; first episode psychosis; universal prevention; selective prevention; indicated prevention; outcomes; clinical staging; CLINICAL HIGH-RISK; ULTRA-HIGH RISK; RANDOMIZED-CONTROLLED-TRIAL; ACTING INJECTABLE ANTIPSYCHOTICS; 1ST EPISODE PSYCHOSIS; 10-YEAR FOLLOW-UP; EARLY INTERVENTION; TREATMENT RESPONSE; UNTREATED PSYCHOSIS; ORAL ANTIPSYCHOTICS;
D O I
10.1002/wps.20446
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Outcomes of psychotic disorders are associated with high personal, familiar, societal and clinical burden. There is thus an urgent clinical and societal need for improving those outcomes. Recent advances in research knowledge have opened new opportunities for ameliorating outcomes of psychosis during its early clinical stages. This paper critically reviews these opportunities, summarizing the state-of-the-art knowledge and focusing on recent discoveries and future avenues for first episode research and clinical interventions. Candidate targets for primary universal prevention of psychosis at the population level are discussed. Potentials offered by primary selective prevention in asymptomatic subgroups (stage 0) are presented. Achievements of primary selected prevention in individuals at clinical high risk for psychosis (stage 1) are summarized, along with challenges and limitations of its implementation in clinical practice. Early intervention and secondary prevention strategies at the time of a first episode of psychosis (stage 2) are critically discussed, with a particular focus on minimizing the duration of untreated psychosis, improving treatment response, increasing patients' satisfaction with treatment, reducing illicit substance abuse and preventing relapses. Early intervention and tertiary prevention strategies at the time of an incomplete recovery (stage 3) are further discussed, in particular with respect to addressing treatment resistance, improving well-being and social skills with reduction of burden on the family, treatment of comorbid substance use, and prevention of multiple relapses and disease progression. In conclusion, to improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre-emptive interventions to high-risk groups identified across the early stages of the disorder. Only a systematic implementation of these models of care in the national health care systems will render these strategies accessible to the 23 million people worldwide suffering from the most severe psychiatric disorders.
引用
收藏
页码:251 / 265
页数:15
相关论文
共 181 条
[71]   The Psychosis High-Risk State A Comprehensive State-of-the-Art Review [J].
Fusar-Poli, Paolo ;
Borgwardt, Stefan ;
Bechdolf, Andreas ;
Addington, Jean ;
Riecher-Rossler, Anita ;
Schultze-Lutter, Frauke ;
Keshavan, Matcheri ;
Wood, Stephen ;
Ruhrmann, Stephan ;
Seidman, Larry J. ;
Valmaggia, Lucia ;
Cannon, Tyrone ;
Velthorst, Eva ;
De Haan, Lieuwe ;
Cornblatt, Barbara ;
Bonoldi, Ilaria ;
Birchwood, Max ;
McGlashan, Thomas ;
Carpenter, William ;
McGorry, Patrick ;
Klosterkotter, Joachim ;
McGuire, Philip ;
Yung, Alison .
JAMA PSYCHIATRY, 2013, 70 (01) :107-120
[72]   Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials [J].
Fusar-Poli, Paolo ;
Kempton, Matthew J. ;
Rosenheck, Robert A. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (02) :57-66
[73]   Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial [J].
Galderisi, Silvana ;
Mucci, Armida ;
Bitter, Istvan ;
Libiger, Jan ;
Bucci, Paola ;
Fleischhacker, W. Wolfgang ;
Kahn, Rene S. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (03) :196-204
[74]   Schizophrenia and complications of pregnancy and labor:: An individual patient data meta-analysis [J].
Geddes, JR ;
Verdoux, H ;
Takei, N ;
Lawrie, SM ;
Bovet, P ;
Eagles, JM ;
Heun, R ;
McCreadie, RG ;
McNeil, TF ;
O'Callaghan, E ;
Stöber, G ;
Willinger, U ;
Murray, RM .
SCHIZOPHRENIA BULLETIN, 1999, 25 (03) :413-423
[75]   A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis [J].
Gleeson, John F. M. ;
Alvarez-Jimenez, Mario ;
Cotton, Sue M. ;
Parker, Alexandra G. ;
Hetrick, Sarah .
SCHIZOPHRENIA RESEARCH, 2010, 119 (1-3) :79-88
[76]  
GORDON RS, 1983, PUBLIC HEALTH REP, V98, P107
[77]   Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study [J].
Grawe, R. W. ;
Falloon, I. R. H. ;
Widen, J. H. ;
Skogvoll, E. .
ACTA PSYCHIATRICA SCANDINAVICA, 2006, 114 (05) :328-336
[78]   Does tobacco use cause psychosis? Systematic review and meta-analysis [J].
Gurillo, Pedro ;
Jauhar, Sameer ;
Murray, Robin M. ;
MacCabe, James H. .
LANCET PSYCHIATRY, 2015, 2 (08) :718-725
[79]   First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies [J].
Haddad, Peter M. ;
Taylor, Mark ;
Niaz, Omair S. .
BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 :S20-S28
[80]   Treatment resistant schizophrenia: Course of brain structure and function [J].
Harvey, Philip D. ;
Rosenthal, Jennifer B. .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2016, 70 :111-116